In conclusion, we developed a novel and simple drug delivery system with a dual-targeting mechanism that allows deep penetration into the tumor tissue and effective homing of STING agonists to the glioma once across the BBB, providing a promising immunotherapeutic strategy for the treatment of glioma. The gene discussed is STING1; the disease is neoplasm.